Charles River Laboratories International (CRL) Could Be 8% Undervalued After Endosafe Automation Ramp
What the new Endosafe automation means for Charles River Laboratories International investors
Charles River Laboratories International (CRL) just brought its Endosafe Cartridge Technology Automated Manufacturing Suite to full capacity, putting automated endotoxin testing and digital traceability at the center of its cartridge production operations.
The project targets higher throughput, tighter quality control, and more detailed data on every cartridge. This matters for investors watching how the business manages costs, reliability, and long-run demand in its Manufacturing Solutions segment.
Against this operational backdrop, Charles River Laboratories International’s recent share price momentum has been strong. The stock is up 7.85% on a 1-month share price return and 54.87% on a 3-month share price return, while the 1-year total shareholder return of 83.31% points to sustained optimism, despite a weaker 5-year total shareholder return showing a 33.87% decline.
Scan beyond Charles River Laboratories International and see how other quality-focused manufacturers are responding to automation tailwinds with the hand-picked 83 resilient stocks with low risk scores.
Charles River Laboratories International now trades just above the average analyst target and slightly below one intrinsic value estimate. After such a sharp move, where does a reasonable fair value range really sit for this stock?
Most Popular Narrative: 8% Undervalued
At a last close of $288.50 against a fair value narrative of $313.61, Charles River Laboratories International is framed as modestly undervalued by its most followed thesis.
The Hidden Bottleneck in Drug Development: Why Charles River Acquired a Cambodian Primate Supplier
On January 12, 2026, Charles River Laboratories announced that it had signed an agreement to acquire the assets of K.F. (Cambodia) Ltd., a major non-human primate (NHP) breeding and supply company. [$510M]
At first glance, this transaction might appear to be a routine supply chain acquisition in the contract research organization (CRO) industry. However, the deeper implication is far more significant.
Want to understand why this narrative prices Charles River Laboratories International above today’s quote? The fair value rests on expectations of faster earnings recovery, improving margins, and a richer profit multiple once losses reverse.
Result: Fair Value of $313.61 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
Still, the narrative could crack if Charles River Laboratories International faces tighter NHP regulations, or if ethical concerns shrink long term demand for primate research.
Find out about the key risks to this Charles River Laboratories International narrative.
Next Steps
Mixed messages in this Charles River Laboratories International story, with both concerns and bright spots in play, mean your own read of the data matters. To see the full balance of potential upside against the issues investors are watching, review the 3 key rewards and 2 important warning signs.
Looking for more investment ideas beyond Charles River Laboratories International?
If you only focus on Charles River Laboratories International, you risk missing other compelling setups that could better fit your time horizon and risk tolerance.
- Target potential upside in quality companies trading below their assessed worth by scanning the 49 high quality undervalued stocks.
- Prioritize resilience and sleep-better-at-night holdings by reviewing the list of solid balance sheet and fundamentals (24 results).
- Hunt for under the radar opportunities with strong fundamentals using the 17 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com